TerminatedPhase 2

POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU

Stopped: Terminated based on interim efficacy data that did not meet the Sponsor's criteria.

United States36 participantsStarted 2023-06-14

Plain-language summary

This is a multi-center, randomized, double-masked, proof-of-concept study in patients with Active Noninfectious Intermediate, Posterior, or Panuveitis.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Active inflammatory chorioretinal and/or inflammatory retinal vascular lesion or lesions, or
✓. ≥ 2+ VH in accordance with the NEI/SUN criteria

What they're measuring

To compare the efficacy between 2 ESK-001 treatment groups for the treatment of active NIU as measured by the proportion of patients failing treatment by Week 24

Timeframe: 24 Weeks

Trial details

NCT IDNCT05953688

SponsorAlumis Inc

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-08-13

View on ClinicalTrials.gov More Uveitis Posterior Non-Infectious trials